HPV Testing & PAP Test Market Analysis and Forecast to 2032: By Test Type (HPV Test, PAP Test, Co-test), Application (Cervical Cancer, Vaginal Cancer), Location of Testing (Hospitals & Clinics, Diagnostic Centers, Others), and Region

HPV Testing & PAP Test Market Analysis and Forecast to 2032: By Test Type (HPV Test, PAP Test, Co-test), Application (Cervical Cancer, Vaginal Cancer), Location of Testing (Hospitals & Clinics, Diagnostic Centers, Others), and Region

The global HPV testing & PAP test market was valued at USD 3.7 billion in 2022 and it is anticipated to grow further till USD 7.2 billion by 2032, at a CAGR of 6.8% during the forecast period.

The most prevalent sexually transmitted infection in the world is caused by the papillomaviridae family's Human Papillomavirus (HPV). A double-stranded DNA tumor virus called the human papillomavirus promotes the growth of epithelial cells on the cutaneous and mucosal surfaces. HPV is divided into two categories, such as low-risk HPVs and high-risk HPVs, depending on the risk involved. About 14 HPV varieties, including HPV 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68, are considered high-risk. Cervical and vaginal cancers are now well known to be caused by high-risk strains of the HPV virus. The most oncogenic HPV type, HPV 16, causes over half of all cervical cancers, and HPV 16 and 18 together cause around 70% of cervical cancers.
Global HPV Testing & PAP Test Market Scope and Report Structure
Market Driver and Trends
The rise in cervical cancer incidences worldwide, the expansion of cervical cancer screening programmes, and the adoption of cutting-edge technology are the market's main growth drivers. The World Health Organization (WHO) estimates that more than 500,000 women will get cervical cancer in 2020, and 342,000 will pass away as a result. In accordance with the World Health Assembly's endorsement of WHO's global strategy for eradicating cervical cancer in 2020, 70% of women worldwide must undergo routine high-performance cervical cancer screenings, and 90% of those who do so must receive the necessary treatment, which may include surgery.
Market Restraints and Challenges
The approved tests that are marketed to women are for cervical cancer screening. They are not helpful for men's genital warts or malignancies linked to HPV. The market's growth has been constrained to one gender due to the selective product availability, resulting in sluggish growth over the projection period.

Global HPV Testing & PAP Test Market Segmental Overview
The global HPV testing & PAP test market is segmented into test type, application, location of testing, and region.

Global HPV Testing & PAP Test Market by Test Type

Based on test type, it is segmented into HPV test, PAP test, and Co-test. The HPV test segment is anticipated to dominate the market during the forecast period. Similarly, PAP test segment is anticipated to witness the fastest growth during the forecast period.

Global HPV Testing & PAP Test Market by Application

Based on the application, it is segmented into cervical cancer, and vaginal cancer. The cervical cancer segment is anticipated to dominate the market during the forecast period. Similarly, vaginal cancer segment is anticipated to witness the fastest growth during the forecast period.

Global HPV Testing & PAP Test Market by Location of Testing

Based on location of testing, it is segmented into hospitals & clinics, diagnostic centers, and others. The hospitals & clinics segment is anticipated to dominate the market during the forecast period. Similarly, diagnostic centers segment is anticipated to witness the fastest growth during the forecast period.
Geographical Analysis of the Global HPV Testing & PAP Test Market

Region-wise, it is studied across North America, Europe, Asia Pacific, and the Rest of the World. The North America region is anticipated to dominate the market during the forecast period. Similarly, the Asia Pacific region is anticipated to witness the fastest growth during the forecast period.
Major Players in the Global HPV Testing & PAP Test Market
The report analyses various key players such as Arbor Vita Corporation, Danaher Corporation (Cepheid), Seegene Inc., Becton, Dickinson and Company, TruScreen, Abbott Laboratories, Hologic Inc., Qiagen NV, F. Hoffmann-La Roche AG, and OncoHealth Corporation among others.
COVID-19 Impact
On the market, the COVID-19 epidemic had a considerable effect. Healthcare services, especially the identification of numerous ailments, decreased as a result of the lockdown and suspension of trade in many nations. With the COVID-19 pandemic spreading across the globe in 2020, it was discovered that many elective medical procedures, including cancer screening, were mostly postponed in order to prioritise other essential requirements and lower the chance of COVID-19 spreading. This has revealed a marked decrease in cancer screening. The primary concerns of national healthcare organisations and global healthcare systems, however, have been cancer care and upholding high standards for diagnosis and treatment.
Recent Developments

June 2022, Roche announced the launch of a human papillomavirus (HPV) self-sampling solution in countries accepting the CE mark. This new solution enables a patient to privately collect sample for HPV screening. The clinically-validated vaginal sample is analysed with the Roche cobas HPV test on a Roche molecular instrument.
May 2021, Becton, Dickinson, and Company announced that the industry's first self-collection claim for HPV screening has been CE marked to the IVD directive 98/79/EC. The new claim allows laboratories and facilities to process self-collected samples via a BD diluent tube using the BD Onclarity HPV Assay on either the BD Viper LT or the BD COR System.
July 2020, BD announced that it received approval for a pre-market approval supplement from the U.S. Food and Drug Administration (FDA) for an expanded version of its BD Onclarity HPV Assay.

Frequently Asked Questions
Q1. How big is the HPV Testing & Pap Test market?

Ans. The global HPV Testing & Pap Test market size was USD 3.7 billion in 2022 and it is anticipated to grow further till USD 7.2 billion by 2032, at a CAGR of 6.8% from 2023 to 2032.

Q2. What is the HPV Testing & Pap Test market growth rate?

Ans. The growth rate of the HPV Testing & Pap Test market is 6.8%.

Q3. Which region holds a major market share for the HPV Testing & Pap Test market?

Ans. North America holds a major market share of the HPV Testing & Pap Test market in 2022.

Q4. Which segment accounted for the largest HPV Testing & Pap Test market share?

Ans. By application, cervical cancer segment accounted for the largest HPV Testing & Pap Test market share.

Q5. Who are the key players in the HPV Testing & Pap Test market?

Ans. The global HPV Testing & Pap Test market report includes players such as Arbor Vita Corporation, Danaher Corporation (Cepheid), Seegene Inc., Becton, Dickinson and Company, TruScreen, Abbott Laboratories, Hologic Inc., Qiagen NV, F. Hoffmann-La Roche AG, and OncoHealth Corporation among others.

Q6. What are the factors driving the HPV Testing & Pap Test market growth?

Ans. The major factors driving the growth of the market are the growing market in emerging countries.

Q7. What are the key growth strategies of HPV Testing & Pap Test market players?

Ans. The key growth strategies of HPV Testing & Pap Test market players are product launch and product approval.

Q8. Which region will provide more business opportunities for the HPV Testing & Pap Test market during the forecast period?

Ans. The Asia-Pacific region will provide more business opportunities for the HPV Testing & Pap Test market during the forecast period.

Please Note: This report will be delivered by publisher within 3-4 business days of order confirmation.